H
Helgi van de Velde
Researcher at Millennium Pharmaceuticals
Publications - 117
Citations - 9725
Helgi van de Velde is an academic researcher from Millennium Pharmaceuticals. The author has contributed to research in topics: Bortezomib & Multiple myeloma. The author has an hindex of 41, co-authored 117 publications receiving 8773 citations. Previous affiliations of Helgi van de Velde include Johnson & Johnson Pharmaceutical Research and Development & Janssen Pharmaceutica.
Papers
More filters
Journal ArticleDOI
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Jesús F. San Miguel,Rudolf Schlag,Nuriet K. Khuageva,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Ivan Spicka,Maria Teresa Petrucci,Antonio Palumbo,Olga Samoilova,Anna Dmoszynska,Kudrat Abdulkadyrov,Rik Schots,Bin Jiang,Maria-Victoria Mateos,Kenneth C. Anderson,Dixie Lee Esseltine,Kevin Liu,Andrew Cakana,Helgi van de Velde,Paul G. Richardson +20 more
TL;DR: Bortezomib plus melphalan-prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy was superior to melphAlan-predisonsone alone.
Journal ArticleDOI
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau,Halyna Pylypenko,Sebastian Grosicki,Ievgenii Karamanesht,Xavier Leleu,Maria Grishunina,Grigoriy B Rekhtman,Zvenyslava Masliak,Tadeusz Robak,Anna V Shubina,Bertrand Arnulf,Martin Kropff,James Cavet,Dixie-Lee Esseltine,Huaibao Feng,Suzette Girgis,Helgi van de Velde,William Deraedt,Jean-Luc Harousseau +18 more
TL;DR: The primary objective was to show non-inferiority of subcutaneous versus intravenous bortezomib in terms of overall response rate (ORR) after four cycles in patients with a diagnosis of measurable, secretory multiple myeloma who received one or more dose of drug.
Journal ArticleDOI
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Philippe Moreau,Tamás Masszi,Norbert Grzasko,Nizar J. Bahlis,Markus Hansson,Ludek Pour,Irwindeep Sandhu,Peter Ganly,Bartrum W Baker,Sharon Jackson,Anne-Marie Stoppa,D. Simpson,Peter Gimsing,Antonio Palumbo,Laurent Garderet,Michele Cavo,Shaji Kumar,Cyrille Touzeau,Francis K. Buadi,Jacob P. Laubach,Deborah Berg,J. Lin,Alessandra Di Bacco,Ai Min Hui,Helgi van de Velde,Paul G. Richardson +25 more
TL;DR: The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression-free survival; the additional toxic effects with this all-oral regimen were limited.
Journal ArticleDOI
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Maria-Victoria Mateos,Paul G. Richardson,Rudolf Schlag,Nuriet K. Khuageva,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Ivan Spicka,Maria Teresa Petrucci,Antonio Palumbo,Olga Samoilova,Anna Dmoszynska,Kudrat Abdulkadyrov,Rik Schots,Bin Jiang,Dixie Lee Esseltine,Kevin Liu,Andrew Cakana,Helgi van de Velde,Jesús F. San Miguel +19 more
TL;DR: VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy, and appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent-based treatment until relapse.
Journal ArticleDOI
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Maria-Victoria Mateos,Maria-Victoria Mateos,J Hernández,J Hernández,Miguel-T Hernandez,Miguel-T Hernandez,Norma-C. Gutiérrez,Norma-C. Gutiérrez,Luis Palomera,Luis Palomera,M. Fuertes,M. Fuertes,Joaquín Díaz-Mediavilla,Joaquín Díaz-Mediavilla,J.J. Lahuerta,J.J. Lahuerta,Javier de la Rubia,Javier de la Rubia,María-José Terol,María-José Terol,Ana Sureda,Ana Sureda,Joan Bargay,Joan Bargay,Paz Ribas,Paz Ribas,Felipe de Arriba,Felipe de Arriba,Adrian Alegre,Adrian Alegre,Albert Oriol,Albert Oriol,Dolores Carrera,Dolores Carrera,José García-Laraña,José García-Laraña,Ramón García-Sanz,Ramón García-Sanz,Joan Bladé,Joan Bladé,Felipe Prosper,Felipe Prosper,G. Mateo,G. Mateo,Dixie-Lee Esseltine,Dixie-Lee Esseltine,Helgi van de Velde,Helgi van de Velde,Jesús-F San Miguel,Jesús-F San Miguel +49 more
TL;DR: In elderly patients ineligible for transplantation, the combination of bortezomib plus MP appears significantly superior to MP, producing very high CR rates, including immunophenotypic CRs, even in patients with poor prognostic features.